A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

PHASE2RecruitingINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Multiple Myeloma, Refractory
Interventions
DRUG

Selinexor

Participants will receive Selinexor oral tablets.

DRUG

Dexamethasone

Participants will receive Dexamethasone oral tablets.

DRUG

Bortezomib

Participants will receive Bortezomib SC injection.

Trial Locations (17)

2654

COMPLETED

University General Hospital of Patras, Pátrai

3108

RECRUITING

Bnai-Zion Medical Center, Haifa

10676

RECRUITING

"General Hospital of Athens Evaggelismos", Athens

11528

RECRUITING

"General Hospital of Athens ALEXANDRA", Attiki

49100

RECRUITING

Rabin Medical Center (Beilinson Hospital), Petah Tikva

52621

RECRUITING

The Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan

54007

RECRUITING

Theageneion Cancer Hospital, Thessaloniki

64239

RECRUITING

Tel Aviv Sourasky Medical Center, Tel Aviv

1834111

RECRUITING

Emek Medical Center, Afula

3109601

RECRUITING

Rambam Health Care Campus, Haifa

4428164

COMPLETED

Meir Medical Center, Kfar Saba

7747629

RECRUITING

Assuta Ashdod Medical Center, Ashdod

7830604

RECRUITING

Barzilai Medical Center, Ashkelon

9103102

RECRUITING

Shaare Zedek Medical Center, Jerusalem

9112001

RECRUITING

Hadassah Medical Center, Jerusalem

115 28

RECRUITING

"General Hospital of Athens Alexandra", Athens

Unknown

ACTIVE_NOT_RECRUITING

Soroka University Medical Center, Beersheba

Sponsors
All Listed Sponsors
lead

Karyopharm Therapeutics Inc

INDUSTRY